167 related articles for article (PubMed ID: 17454621)
1. Denileukin diftitox and vision loss.
Ruddle JB; Prince HM
Leuk Lymphoma; 2007 Apr; 48(4):655-6. PubMed ID: 17454621
[No Abstract] [Full Text] [Related]
2. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
Park M; Liu GT; Piltz-Seymour J; Wisda CL; Rook AH; Junkins-Hopkins JM; Nasta SD; Kim EJ
Leuk Lymphoma; 2007 Apr; 48(4):808-11. PubMed ID: 17454642
[No Abstract] [Full Text] [Related]
3. Denilieukin diftitox vision loss is not posterior ischemic optic neuropathy.
Lubow M; Grzybowski DM; Awad H
Leuk Lymphoma; 2008 Feb; 49(2):370-1; author reply 372. PubMed ID: 18231931
[No Abstract] [Full Text] [Related]
4. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
McCann S; Akilov OE; Geskin L
Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
[TBL] [Abstract][Full Text] [Related]
6. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Walker PL; Dang NH
Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
[TBL] [Abstract][Full Text] [Related]
7. A denileukin diftitox (Ontak) associated retinopathy?
Ruddle JB; Harper CA; Hönemann D; Seymour JF; Prince HM
Br J Ophthalmol; 2006 Aug; 90(8):1070-1. PubMed ID: 16854841
[No Abstract] [Full Text] [Related]
8. New advances in the management of cutaneous T-cell lymphoma.
Young SK
Cancer Pract; 2001; 9(1):52-4. PubMed ID: 11879274
[No Abstract] [Full Text] [Related]
9. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
Carretero-Margolis CD; Fivenson DP
J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
[TBL] [Abstract][Full Text] [Related]
10. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
Kazin R; Bujanauskas P; Vonderheid EC
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
[No Abstract] [Full Text] [Related]
11. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
12. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox.
Dao H; Barr PM; Honda K
J Am Acad Dermatol; 2011 Jun; 64(6):e123-5. PubMed ID: 21571160
[No Abstract] [Full Text] [Related]
13. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.
Duvic M; Martin AG; Olsen EA; Fivenson DP; Prince HM
Leuk Lymphoma; 2013 Mar; 54(3):514-9. PubMed ID: 22891708
[TBL] [Abstract][Full Text] [Related]
15. Autologous graft-versus-host disease after denileukin diftitox and autologous stem cell transplantation for refractory T-cell lymphoma.
Zalom M; Lill M; Lukic D; Balzer BL; Lim S
Leuk Lymphoma; 2009 Jan; 50(1):124-6. PubMed ID: 19117212
[No Abstract] [Full Text] [Related]
16. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
Talpur R; Duvic M
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
[TBL] [Abstract][Full Text] [Related]
17. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
Assaf C
Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
[No Abstract] [Full Text] [Related]
18. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
[TBL] [Abstract][Full Text] [Related]
19. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
20. Denileukin diftitox for the treatment of panniculitic lymphoma.
McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio CC; Rook AH
Arch Dermatol; 2002 Jun; 138(6):740-2. PubMed ID: 12056952
[No Abstract] [Full Text] [Related]
[Next] [New Search]